Holen Sie sich die Stockscreener-App
9.07
0.44%
0.04
Vorhandelsmarkt:
9.03
-0.04
-0.44%
Schlusskurs vom Vortag:
$9.03
Offen:
$9.19
24-Stunden-Volumen:
1.42M
Relative Volume:
1.46
Marktkapitalisierung:
$283.80M
Einnahmen:
$17.50M
Nettoeinkommen (Verlust:
$-58.88M
KGV:
-4.3037
EPS:
-2.1075
Netto-Cashflow:
$-46.16M
1W Leistung:
-22.61%
1M Leistung:
-31.39%
6M Leistung:
-77.34%
1J Leistung:
-65.68%
1-Tages-Spanne:
$8.99
$9.39
1-Wochen-Bereich:
$8.85
$11.88
52-Wochen-Spanne:
$8.85
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
9.07 | 283.80M | 17.50M | -58.88M | -46.16M | -2.1075 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Valuation Update: What is the cash position of LENZ Therapeutics Inc2026 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
LENZ Therapeutics Hits 52-Week Low at $8.86 Amid Ongoing Struggles - Markets Mojo
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price - MarketBeat
LENZ Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
LENZ Therapeutics Reports Fourth Quarter, Full-Year Financial Results as Sales of Presbyopia Drop Gain Momentum - VisionMonday.com
VIZZ by LENZ Therapeutics: FDA-Approved Once-Daily Eye Drop for Presbyopia Treatment and Market Opportunity 32 - Minichart
LENZ Therapeutics (NASDAQ:LENZ) Posts Earnings Results, Misses Expectations By $0.25 EPS - MarketBeat
LENZ Therapeutics 2025 10-K: $19.1M Revenue, $(2.85) EPS - TradingView
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
LENZ: Initial VIZZ launch drove $1.6M sales and $17.5M license revenue, but net loss reached $82.1M - TradingView
VIZZ presbyopia launch propels LENZ Therapeutics (NASDAQ: LENZ) - Stock Titan
LENZ Therapeutics, Inc. (LENZ) reports Q4 loss, misses revenue estimates - MSN
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses - Investing.com UK
LENZ Therapeutics Reports Q4 and Full Year 2025 Results; Launches VIZZ Eye Drop for Presbyopia with Strong Prescription Uptake and Expanding Commercial Infrastructure - Minichart
LENZ Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Why Lenz Therapeutics Stock Crashed Today - The Globe and Mail
LENZ Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: LENZ Therapeutics Q4 2025 sees stock dip amid high expenses By Investing.com - Investing.com India
LENZ: Strong launch momentum, robust cash, and expanding adoption position the product for growth - TradingView
Why Lenz Therapeutics Stock Crashed Today - The Motley Fool
LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch - ChartMill
LENZ Therapeutics, Inc. (LENZ) Reports Wider Q4 Loss Than Expected - AlphaStreet
LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
LENZ Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
LENZ THERAPEUTICS ($LENZ) Releases Q4 2025 Earnings - Quiver Quantitative
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - The Manila Times
VIZZ launch drives first LENZ (NASDAQ: LENZ) product revenue in 2025 - Stock Titan
LENZ: VIZZ launch drove $1.6M in Q4 sales; net loss rose to $82.1M amid major launch investments - TradingView
LENZ Therapeutics Q4 EPS $(1.16) Misses $(0.9... - Benzinga
LENZ Therapeutics Hits 52-Week Low at USD 11.22 Amidst Declining Performance - Markets Mojo
LENZ Therapeutics Hits 52-Week Low at USD 10.44 Amid Ongoing Struggles - Markets Mojo
LENZ Therapeutics, Inc. (LENZ) Announces Fourth Quarter Loss, Falls Short of Revenue Projections - Bitget
Top Wall Street forecasters revamp LENZ Therapeutics expectations ahead of Q4 earnings - MSN
Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings - Benzinga
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
LENZ Therapeutics (NASDAQ:LENZ) Rating Lowered to Sell at Wall Street Zen - MarketBeat
LENZ Therapeutics Inc expected to post a loss of 97 cents a shareEarnings Preview - TradingView
Can LENZ Therapeutics Inc. be the next market leader2026 Big Picture & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026 - The Manila Times
Maker of VIZZ presbyopia eye drop sets March 24 call on 2025 results - Stock Titan
IPO Launch: Is LENZ Therapeutics Inc affected by consumer sentimentMarket Rally & AI Driven Stock Movement Reports - baoquankhu1.vn
693,044 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by First Light Asset Management LLC - MarketBeat
LENZ Therapeutics, Inc. $LENZ is Ally Bridge Group NY LLC's 7th Largest Position - MarketBeat
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ for the Treatment of Presbyopia - marketscreener.com
Performance Recap: Can LENZ Therapeutics Inc reach all time highs this year2026 Historical Comparison & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
LENZ Therapeutics Projected to Post Earnings on WednesdayDel Mar Today - National Today
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
William Blair Maintains Outperform on LENZ Therapeutics, Inc (LENZ) March 10 2026 - Meyka
LENZ submits marketing application for presbyopia drug in Europe - Investing.com South Africa
William Blair reiterates Lenz Therapeutics stock rating on VIZZ potential By Investing.com - Investing.com Canada
LENZ submits marketing application for presbyopia drug in Europe By Investing.com - Investing.com Australia
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):